^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer

Published date:
09/15/2023
Excerpt:
In conclusion, gilteritinib demonstrated significantly improved antitumor efficacy compared with alectinib against ALK-rearranged NSCLC cells…
DOI:
https://doi.org/10.1111/cas.15958